Since over 40% of bladder cancers exhibit constitutive activation of the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) pathway [10,11], suppressing activation is a treatment option [12]. The gene discussed is AKT1; the disease is urinary bladder carcinoma.